Fig. 2: Clinical decision-making flowchart, based on the two-step risk stratification model. | npj Precision Oncology

Fig. 2: Clinical decision-making flowchart, based on the two-step risk stratification model.

From: Who may omit locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a failure-pattern–based strategy in the immunotherapy era

Fig. 2: Clinical decision-making flowchart, based on the two-step risk stratification model.

After first-line immunochemotherapy, patients with a Model I score ≥ two are classified as resistant patients and modification of the treatment strategy is recommended. Those scoring < two proceed to Model II. In Model II, patients with a score of two are considered durable responders and advised to receive immunotherapy maintenance alone, while those with a score < two are identified as partial responders and LRRT is recommended. NPC nasopharyngeal carcinoma, LRRT locoregional radiotherapy, LDH lactate dehydrogenase, EBV Epstein-Barr virus, SD stable disease, PD progressive disease. Depth of response (DpR) was defined as the percentage of tumor shrinkage from the baseline tumor burden to the timepoint of assessment.

Back to article page